A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery

NCT06674252 · tracked via the Priya Life Science China tracker

Sponsor

Peking University Cancer Hospital & Institute

Phase

Not applicable

Started

2025-06-13

Last updated

2026-01-27

Condition(s) studied

Lung Cancers

Investigational drug(s) / intervention(s)

Jiawei Bufei Tang granulesPlacebo

Jiawei Bufei Tang granules: Jiawei Bufei Tang is a traditional Chinese medicine formula applied by Professor Li Pingping to patients with lung cancer and qi yin deficiency syndrome. It consists of Huangqi, Codonopsis pilosula, Schisandra chinensis, Rehmannia glutinosa, Ziyuan, Mulberry bark, Snake berry, Half branch Lotus, White Hedyotis diffusa, etc. Bu Fei Tang is derived from the Yuan Dynasty's "Yong Lei Ling Fang" and consists of six ingredients: ginseng, astragalus, schisandra, Radix Rehmanniae, Ziyuan, and mulberry bark. It is mainly used to treat cough caused by lung qi deficiency. Jiawei Bufei Tang adds white Hedyotis diffusa, Scutellaria barbata, and snake berry to the original formula. White Hedyotis diffusa is more effective in dispelling carbuncles and detoxifying, Scutellaria barbata is more effective in dispelling phlegm and diuresis, and snake berry is more effective in dispelling scrofula and dispersing nodules, increasing the effect of clearing heat and detoxifying. This formula is particularly e

Placebo: placebo

Study summary

This is a randomized double-blind placebo-controlled phase II clinical study that included patients with symptoms such as cough, shortness of breath, and fatigue after lung cancer resection surgery. They were given orally modified Bufei Tang granules twice a day for 28 days, with one packet taken orally with water. Using the MDASI-TCM symptom scoring system, evaluate the scores of symptoms such as cough, shortness of breath, and fatigue before and after the experiment, and calculate the difference in scores between the control group and the experimental group before and after the experiment.

Eligibility

Sex

ALL

Min age

65 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients with postoperative lung cancer who have clear histological or cytological diagnosis. * Age ≥ 65 years old, both male and female are eligible. According to the MDASI-TCM scale evaluation, any of the three symptoms of cough, fatigue, and shortness of breath should score ≥ 4 points, or the sum of the three should score ≥ 6 points. * The heart function is basically normal; ALT/AST is within 2 times the normal value; SCr is within the normal range. Traditional Chinese medicine syndrome differentiation is characterized by deficiency of both lungs and kidneys. Exclusion Criteria: * Patients with severe pulmonary infections. ⑵. Patients with mental illness. ⑶. Patients with depression.

Primary outcome measure(s)

MDASI-TCM scale — 28 days
The symptom score results of the MDASI-TCM scale between the oral Chinese medicine group and the placebo group after 28 days of medication.

Trial sites (2)

Facility	City	Region	Status
Beijing cancer hospital	Beijing	Beijing Municipality	Recruiting
Beijing cancer hospital	Beijing	Beijing Municipality	Recruiting

More Peking University Cancer Hospital & Institute trials in China

Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach Recruiting

68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy Starting soon

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade Recruiting

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy Recruiting

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure Recruiting

Other trials for the same condition

SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis Starting soon

Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI Recruiting

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors Recruiting

⁶⁸Ga-DPA in the Lung Cancer Diagnosis Enrolling by invitation

AI-Assisted Non-Contrast CT for Multi-Cancer Screening Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06674252 on ClinicalTrials.gov ↗ ← All trials in China